Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Healthtrust
Merck
AstraZeneca
Federal Trade Commission
Express Scripts

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,297,018

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,297,018
Title:Chimeric promoters capable of mediating gene expression in plants upon pathogen infection and uses thereof
Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.
Inventor(s): Kirsch; Christoph (Cologne, DE), Logemann; Elke (Pulheim-Dansweiler, DE), Hahlbrock; Klaus (Freiburg, DE), Rushton; Paul (Brookings, SD), Somssich; Imre (Cologne, DE)
Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE)
Application Number:13/930,266
Patent Claims:see list of patent claims

Details for Patent 9,297,018

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04 ➤ Sign Up Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE) 2018-11-12 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04 ➤ Sign Up Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE) 2018-11-12 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04 ➤ Sign Up Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. (Berlin, DE) 2018-11-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Baxter
Argus Health
Mallinckrodt
Chinese Patent Office
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.